Selvita S.A. Stock

Equities

SLV

PLSLVCR00029

Biotechnology & Medical Research

Market Closed - Warsaw S.E. 11:55:44 2024-04-23 am EDT 5-day change 1st Jan Change
69.7 PLN +1.75% Intraday chart for Selvita S.A. -0.43% +19.15%
Sales 2024 * 393M 96.82M Sales 2025 * 505M 125M Capitalization 1.26B 310M
Net income 2024 * 18M 4.44M Net income 2025 * 43M 10.6M EV / Sales 2024 * 3.68 x
Net Debt 2024 * 188M 46.44M Net Debt 2025 * 233M 57.54M EV / Sales 2025 * 2.95 x
P/E ratio 2024 *
18 x
P/E ratio 2025 *
29.1 x
Employees 886
Yield 2024 *
-
Yield 2025 *
-
Free-Float 78.68%
More Fundamentals * Assessed data
Dynamic Chart
1 week-2.14%
Current month+2.70%
1 month+10.84%
3 months+14.17%
6 months+10.13%
Current year+17.09%
More quotes
1 week
67.00
Extreme 67
70.90
1 month
61.10
Extreme 61.1
72.00
Current year
57.00
Extreme 57
72.00
1 year
55.40
Extreme 55.4
77.80
3 years
54.60
Extreme 54.6
91.60
5 years
18.00
Extreme 18
91.60
10 years
18.00
Extreme 18
91.60
More quotes
Managers TitleAgeSince
Chief Executive Officer - 07-08-31
Director of Finance/CFO - 19-07-31
Chief Operating Officer - 09-01-01
Members of the board TitleAgeSince
Director/Board Member 47 19-09-18
Director/Board Member - 19-09-18
Director/Board Member 72 -
More insiders
Date Price Change Volume
24-04-23 69.7 +1.75% 15 605
24-04-22 68.5 -2.28% 1,194
24-04-19 70.1 +1.45% 1,357
24-04-18 69.1 0.00% 1,963
24-04-17 69.1 -1.29% 6,681

Delayed Quote Warsaw S.E., April 23, 2024 at 03:15 am EDT

More quotes
Selvita SA, formerly Selvita Cro SA, is a Poland-based integrated service company active in the pharmaceutical and biotechnology industries. The Company is engaged in providing multidisciplinary solutions supporting customers and projects within area of drug discovery, regulatory studies, as well as research and development. It offers its clients drug discovery support at every stage of the early discovery phase up to preclinical research, from target validation up to the selection of a clinical candidate. Also, it offers services at every stage of the drug discovery process in the field of drug testing and bioanalytical analyses, from development and validation of methods, stability studies, to routine quality control testing. The Company cooperates with numerous research institutes and universities from Europe and the United States.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
68.5 PLN
Average target price
71.28 PLN
Spread / Average Target
+4.06%
Consensus

Quarterly revenue - Rate of surprise